87 related articles for article (PubMed ID: 26268909)
1. CCR2 inhibition: a panacea for diabetic kidney disease?
Weir MR
Lancet Diabetes Endocrinol; 2015 Sep; 3(9):666-7. PubMed ID: 26268909
[No Abstract] [Full Text] [Related]
2. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.
de Zeeuw D; Bekker P; Henkel E; Hasslacher C; Gouni-Berthold I; Mehling H; Potarca A; Tesar V; Heerspink HJ; Schall TJ;
Lancet Diabetes Endocrinol; 2015 Sep; 3(9):687-96. PubMed ID: 26268910
[TBL] [Abstract][Full Text] [Related]
3. CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice.
Sullivan T; Miao Z; Dairaghi DJ; Krasinski A; Wang Y; Zhao BN; Baumgart T; Ertl LS; Pennell A; Seitz L; Powers J; Zhao R; Ungashe S; Wei Z; Boring L; Tsou CL; Charo I; Berahovich RD; Schall TJ; Jaen JC
Am J Physiol Renal Physiol; 2013 Nov; 305(9):F1288-97. PubMed ID: 23986513
[TBL] [Abstract][Full Text] [Related]
4. An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes.
Sayyed SG; Ryu M; Kulkarni OP; Schmid H; Lichtnekert J; Grüner S; Green L; Mattei P; Hartmann G; Anders HJ
Kidney Int; 2011 Jul; 80(1):68-78. PubMed ID: 21508925
[TBL] [Abstract][Full Text] [Related]
5. Cilostazol reduces microalbuminuria in type 2 diabetic nephropathy.
Jiao XM; Jiao XJ; Zhang XG; Xu XP; Wu JX; Yao L; Zhao J; Lü XF
Chin Med J (Engl); 2013 Nov; 126(22):4395-6. PubMed ID: 24238537
[No Abstract] [Full Text] [Related]
6. [Effect of breviscapine on urinary micro-albumine in patients with diabetes mellitus type 2].
Kang SQ; Liu JY
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2003 Jun; 23(6):458-9. PubMed ID: 12872404
[No Abstract] [Full Text] [Related]
7. Finerenone for Albuminuria in Patients With Diabetic Nephropathy.
Feng Y; Zeng X; Fu P
JAMA; 2016 Jan; 315(3):305-6. PubMed ID: 26784783
[No Abstract] [Full Text] [Related]
8. Finerenone for Albuminuria in Patients With Diabetic Nephropathy--Reply.
Bakris GL; Nowack C
JAMA; 2016 Jan; 315(3):306. PubMed ID: 26784785
[No Abstract] [Full Text] [Related]
9. Diabetic nephropathy: Nonsteroidal MRA added to RAS blockade reduces albuminuria.
Weir MR
Nat Rev Nephrol; 2015 Dec; 11(12):691-2. PubMed ID: 26460357
[No Abstract] [Full Text] [Related]
10. Adequate vascular repair is relevant to improving renal perfusion and function following vasodilators in normoalbuminuric type 2 diabetic nephropathy.
Futrakul N; Futrakul P
Am J Kidney Dis; 2009 Sep; 54(3):583-4. PubMed ID: 19700066
[No Abstract] [Full Text] [Related]
11. [Prospective treatment study of irbesartan. Diabetic kidneys regain function].
Lehnert H; Bramlage P; Pittrow D; Kirch W
MMW Fortschr Med; 2003 Oct; 145(41):41. PubMed ID: 14655481
[No Abstract] [Full Text] [Related]
12. [Type 2 diabetic patient with kidney damage. Sartans banish dialysis risk].
MMW Fortschr Med; 2004 Jul; 146(27-28):56. PubMed ID: 15526676
[No Abstract] [Full Text] [Related]
13. Effect of losartan on plasma C-reactive protein in type 2 diabetic patients with microabluminuria.
Tan K; Chow WS; Wong Y; Shiu S; Tam S
Diabetes Care; 2002 Jul; 25(7):1254-5. PubMed ID: 12087039
[No Abstract] [Full Text] [Related]
14. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients.
Cooper ME
J Hypertens Suppl; 1996 Dec; 14(6):S11-4. PubMed ID: 9023709
[TBL] [Abstract][Full Text] [Related]
15. Accounting for Missing Data in Clinical Research.
Stevens JR; Suyundikov A; Slattery ML
JAMA; 2016 Feb; 315(5):517-8. PubMed ID: 26836740
[No Abstract] [Full Text] [Related]
16. Accounting for Missing Data in Clinical Research--Reply.
Newgard CD; Lewis RJ
JAMA; 2016 Feb; 315(5):518. PubMed ID: 26836743
[No Abstract] [Full Text] [Related]
17. Effects of taurine and vitamin E on microalbuminuria, plasma metalloproteinase-9, and serum type IV collagen concentrations in patients with diabetic nephropathy.
Nakamura T; Ushiyama C; Suzuki S; Shimada N; Ohmuro H; Ebihara I; Koide H
Nephron; 1999; 83(4):361-2. PubMed ID: 10575300
[No Abstract] [Full Text] [Related]
18. Peroxisome proliferator-activated receptor-δ activation ameliorates albuminuria by preventing nephrin loss and restoring podocyte integrity in type 2 diabetes.
Lee EY; Kim GT; Hyun M; Kim S; Seok S; Choi R; Lee MY; Chung CH
Nephrol Dial Transplant; 2012 Nov; 27(11):4069-79. PubMed ID: 22892126
[TBL] [Abstract][Full Text] [Related]
19. Podocyte-specific chemokine (C-C motif) receptor 2 overexpression mediates diabetic renal injury in mice.
You H; Gao T; Raup-Konsavage WM; Cooper TK; Bronson SK; Reeves WB; Awad AS
Kidney Int; 2017 Mar; 91(3):671-682. PubMed ID: 27914709
[TBL] [Abstract][Full Text] [Related]
20. Omacor, n-3 polyunsaturated fatty acid, attenuated albuminuria and renal dysfunction with decrease of SREBP-1 expression and triglyceride amount in the kidney of type II diabetic animals.
Chin HJ; Fu YY; Ahn JM; Na KY; Kim YS; Kim S; Chae DW
Nephrol Dial Transplant; 2010 May; 25(5):1450-7. PubMed ID: 20042400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
